Prophylactic Management of Migraine in Lactating Women

First‑Line Prophylaxis

Propranolol is the preferred first‑line preventive medication for migraine without aura in lactating women, offering the most favorable safety profile among all available agents (Nature Reviews Neurology guidelines, 2021) 1.
Recommended dose: 80–160 mg orally once or twice daily in an extended‑release formulation (high‑quality evidence, strong recommendation) [1][2].
Safety evidence: Systematic reviews show propranolol has the best lactation safety data compared with other migraine preventives (high‑quality evidence) [1][2][3][4]5.

Avoid propranolol in patients with asthma, heart failure, Raynaud’s phenomenon, atrioventricular block, or depression (moderate‑quality evidence) [1][2].

Amitriptyline may be used at 10–100 mg orally at night (moderate‑quality evidence) [1][2]4.
Monitoring requirement: Initiation should occur under specialist supervision with careful infant safety monitoring (moderate‑quality evidence) [1][2][4][5].
Contraindications for amitriptyline: heart failure, concomitant monoamine‑oxidase inhibitor or SSRI therapy, and glaucoma (moderate‑quality evidence) [1][2].

Metoprolol – 50–100 mg orally twice daily or 200 mg modified‑release once daily (moderate‑quality evidence) [1][2].
Atenolol – 25–100 mg orally twice daily; use with caution as some data suggest a less favorable lactation profile (moderate‑quality evidence) [1][2].

Topiramate – explicitly contraindicated for lactating mothers (high‑quality evidence) [1][2][3][4]6.
Sodium valproate – contraindicated in women of child‑bearing potential and during lactation (high‑quality evidence) [1][2][4][6].
Candesartan – associated with adverse fetal effects; should be avoided while breastfeeding (high‑quality evidence) [1][2][4][5].

Start with a low dose and titrate gradually to achieve adequate migraine control (strong recommendation) 7.
Specialist supervision is recommended when beginning any preventive therapy during lactation (moderate‑quality evidence) [1][2][4][5].
Assess efficacy after 2–3 months of therapy to determine whether the preventive regimen is effective (moderate‑quality evidence) [6][7].

Paracetamol is the preferred acute medication (high‑quality evidence) [1][2][3][4]5.
Ibuprofen is also considered safe for acute attacks (high‑quality evidence) [1][2][3][4]5.
Sumatriptan may be used safely for acute migraine relief (high‑quality evidence) [1][2][3][4]5.

Encourage adequate hydration, regular sleep, consistent meals, regular moderate‑to‑intense aerobic exercise, and stress‑management techniques as adjuncts to pharmacologic therapy (moderate‑quality evidence) [8][9][10][11].

Discuss risks and benefits of all pharmacologic options with the patient before initiation (strong recommendation) [7][8][9][10]11.
Limit acute medication use to ≤15 days/month for NSAIDs and ≤10 days/month for triptans to avoid medication‑overuse headache (moderate‑quality evidence) [8][9][10][11].
Avoid opioids and butalbital for acute migraine treatment in lactating women (strong recommendation) [8][9][10][11].